| Literature DB >> 36249082 |
Muhammad Asam Raza1, Umme Farwa1, Nida Qurat Ul Ain1, Fatima Ishaque1, Muhammad Yaseen2, Muhammad Naveed3, Muhammad Aqib Shabbir3.
Abstract
In silico studies in terms of density functional theory (DFT), molecular docking, and ADMET (absorption, distribution, metabolism, excretion and toxicity) were performed for 55 thiazolidinones compounds derived from different amines and aldehydes. DFT is a computational quantum mechanical modeling method used to predict the various properties of the compounds. Different parameters such as Electronegativity (x), Chemical Hardness (ŋ), Chemical Potential (μ), Ionization potential (IP), and Electron Affinity (EA), etc. were calculated by Koopmans theorem. The compounds were docked with Molecular Operating Environment (MOE) software using already reported PDB files of BChE, AChE, and α-glucosidase. To analyze the Spike Glycoprotein of SARS-Cov-2 and heterocyclic compounds, molecular interactions study was carried out between Spike Glycoprotein of SARS-Cov-2 (6VXX) and 55 synthetic heterocyclic compounds. It was performed by the utilization of PyRx Virtual Screening Tool and AutoDock Vina based virtual environment was used in PyRx. Maximum binding affinity was observed with compound A7 which was -8.7 kcal/mol and then with A5 which was -8.5 respectively. In the case of the AChE enzyme, B5 has a maximum docking score of -12.9027 kcal/mol while C7 depicted the maximum score for the BChE enzyme with a value of -8.6971 kcal/mol. The docking studies revealed that C6 compound has maximum binding capacity toward glucosidase (-14.8735 kcal/mol). ADMET properties of under consideration compounds were determined by Swiss online-based software which concluded that these molecules have a drug-like properties and having no violation.Entities:
Keywords: COVID-19; DFT; In silico studies; Molecular Docking; Thiazolidinone
Year: 2022 PMID: 36249082 PMCID: PMC9538587 DOI: 10.1002/slct.202201793
Source DB: PubMed Journal: ChemistrySelect ISSN: 2365-6549 Impact factor: 2.307
Scheme 1The synthetic scheme for the synthesized and proposed compounds.
HOMO, LUMO, and Electrochemical properties of the hypothetical A series compounds.
|
Properties |
A |
A1 |
A2 |
A3 |
A4 |
A5 |
A6 |
A7 |
A8 |
A9 |
A10 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
μ (chemical potential) |
−0.21786 |
−0.16517 |
−0.15902 |
−0.16317 |
−0.16932 |
−0.15877 |
−0.15691 |
−0.14071 |
−0.15854 |
−0.15648 |
−0.16055 |
|
ŋ (chemical hardness) |
−0.04906 |
−0.06748 |
−0.06908 |
−0.06407 |
−0.06298 |
−0.06388 |
−0.06068 |
−0.05719 |
−0.06349 |
−0.06282 |
−0.06434 |
|
1/2ŋ (chemical Softness) |
−10.1916 |
−7.41015 |
−7.23851 |
−7.80457 |
−7.93903 |
−7.82779 |
−8.24063 |
−8.74279 |
−7.87588 |
−7.95925 |
−7.77182 |
|
X (electronegativity) |
0.21786 |
0.165165 |
0.159015 |
0.163165 |
0.16932 |
0.158765 |
0.156905 |
0.14071 |
0.158535 |
0.15648 |
0.160545 |
|
HOMO |
−0.26692 |
−0.23264 |
−0.22809 |
−0.22723 |
−0.2323 |
−0.22264 |
−0.21758 |
−0.1979 |
−0.22202 |
−0.2193 |
−0.22488 |
|
LUMO |
−0.1688 |
−0.09769 |
−0.08994 |
−0.0991 |
−0.10634 |
−0.09489 |
−0.09623 |
−0.08352 |
−0.09505 |
−0.09366 |
−0.09621 |
|
(LUMO‐HOMO) |
0.09812 |
0.13495 |
0.13815 |
0.12813 |
0.12596 |
0.12775 |
0.12135 |
0.11438 |
0.12697 |
0.12564 |
0.12867 |
|
Energy gap (eV) |
0.003606 |
0.00496 |
0.005077 |
0.004709 |
0.00462 |
0.00469 |
0.00446 |
0.00420 |
0.00466 |
0.00461 |
0.00472 |
|
IP (ionization potential) |
0.26692 |
0.23264 |
0.22809 |
0.22723 |
0.2323 |
0.22264 |
0.21758 |
0.1979 |
0.22202 |
0.2193 |
0.22488 |
|
EA (electron affinity) |
0.1688 |
0.09769 |
0.08994 |
0.0991 |
0.10634 |
0.09489 |
0.09623 |
0.08352 |
0.09505 |
0.09366 |
0.09621 |
|
Electrophilicity index (ω) |
−0.48372 |
−0.20215 |
−0.18303 |
−0.20778 |
−0.22761 |
−0.19731 |
−0.20288 |
−0.1731 |
−0.19795 |
−0.19489 |
−0.20032 |
|
Maximum charge transfer(▵Nmax) |
−4.44068 |
−2.4478 |
−2.30206 |
−2.54687 |
−2.68847 |
−2.48556 |
−2.58599 |
−2.4604 |
−2.4972 |
−2.49093 |
−2.49545 |
HOMO, LUMO, and Electrochemical properties of the hypothetical B series compounds.
|
Properties |
B |
B1 |
B2 |
B3 |
B4 |
B5 |
B6 |
B7 |
B8 |
B9 |
B10 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
μ (chemical potential) |
−0.2179 |
−0.16301 |
−0.15707 |
−0.1614 |
−0.16739 |
−0.15701 |
−0.15574 |
−0.13966 |
−0.15777 |
−0.15529 |
−0.15869 |
|
ŋ (chemical hardness) |
−0.049 |
−0.06683 |
−0.06861 |
−0.06377 |
−0.06247 |
−0.06337 |
−0.06078 |
−0.05731 |
−0.06342 |
−0.06284 |
−0.06373 |
|
1/2ŋ (chemical Softness) |
−10.204 |
−7.48167 |
−7.28757 |
−7.84068 |
−8.00384 |
−7.89079 |
−8.22639 |
−8.72524 |
−7.88457 |
−7.95672 |
−7.84621 |
|
X (electronegativity) |
0.21791 |
0.16301 |
0.15707 |
0.1614 |
0.16739 |
0.157005 |
0.15574 |
0.13966 |
0.15776 |
0.1553 |
0.15868 |
|
HOMO |
−0.2669 |
−0.22984 |
−0.22568 |
−0.22517 |
−0.22986 |
−0.22037 |
−0.21652 |
−0.19696 |
−0.22118 |
−0.2181 |
−0.22241 |
|
LUMO |
−0.1689 |
−0.09618 |
−0.08846 |
0.09763 |
−0.10492 |
−0.09364 |
−0.09496 |
−0.08235 |
−0.09435 |
−0.0925 |
−0.09496 |
|
(LUMO‐HOMO) |
0.09800 |
0.13366 |
0.13722 |
0.12754 |
0.12494 |
0.12673 |
0.12156 |
0.11461 |
0.12683 |
0.1257 |
0.12745 |
|
Energy gap (eV) |
0.00360 |
0.00491 |
0.00504 |
0.00469 |
0.00459 |
0.00466 |
0.00447 |
0.00421 |
0.00466 |
0.0046 |
0.00468 |
|
IP (ionization potential) |
0.26691 |
0.22984 |
0.22568 |
0.22517 |
0.22986 |
0.22037 |
0.21652 |
0.19696 |
0.22118 |
0.21813 |
0.22241 |
|
EA (electron affinity) |
0.16891 |
0.09618 |
0.08846 |
0.09763 |
0.10492 |
0.09364 |
0.09496 |
0.08235 |
0.09435 |
0.09245 |
0.09496 |
|
Electrophilicity index (ω) |
−0.4845 |
−0.1988 |
−0.17979 |
−0.20425 |
−0.22426 |
−0.19451 |
−0.19953 |
−0.17017 |
−0.19625 |
−0.19188 |
−0.19757 |
|
Maximum charge transfer (▵Nmax) |
−4.4471 |
−2.43917 |
−2.28932 |
−2.53097 |
−2.67953 |
−2.47779 |
−2.56236 |
−2.43705 |
−2.48782 |
−2.4712 |
−2.49015 |
HOMO, LUMO, and Electrochemical properties of the hypothetical C series compounds.
|
Properties |
C |
C1 |
C2 |
C3 |
C4 |
C5 |
C6 |
C7 |
C8 |
C9 |
C10 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
μ (chemical potential) |
−0.23412 |
−0.16291 |
−0.15747 |
−0.16149 |
−0.16698 |
−0.15759 |
−0.15529 |
−0.1406 |
−0.15802 |
−0.15561 |
−0.1592 |
|
ŋ (chemical hardness) |
−0.03288 |
−0.06529 |
−0.06758 |
−0.06261 |
−0.06086 |
−0.06293 |
−0.06114 |
−0.05724 |
−0.06315 |
−0.06275 |
−0.06323 |
|
1/2ŋ (chemical Softness) |
−15.2068 |
−7.65873 |
−7.39864 |
−7.98594 |
−8.21558 |
−7.94597 |
−8.17862 |
−8.73591 |
−7.91828 |
−7.96876 |
−7.90764 |
|
X (electronegativity) |
0.23412 |
0.162905 |
0.15747 |
0.16149 |
0.16698 |
0.157585 |
0.15528 |
0.14059 |
0.158015 |
0.155605 |
0.1592 |
|
HOMO |
−0.267 |
−0.22819 |
−0.22505 |
−0.2241 |
−0.22784 |
−0.22051 |
−0.21642 |
−0.19783 |
−0.22116 |
−0.21835 |
−0.22243 |
|
LUMO |
−0.20124 |
−0.09762 |
−0.08989 |
−0.09888 |
−0.10612 |
−0.09466 |
−0.09415 |
−0.08336 |
−0.09487 |
−0.09286 |
−0.09597 |
|
(LUMO‐HOMO) |
0.06576 |
0.13057 |
0.13516 |
0.12522 |
0.12172 |
0.12585 |
0.12227 |
0.11447 |
0.12629 |
0.12549 |
0.12646 |
|
Energy gap (eV) |
0.002417 |
0.004799 |
0.004967 |
0.004602 |
0.004473 |
0.004625 |
0.00449 |
0.004207 |
0.004641 |
0.004612 |
0.00465 |
|
IP (ionization potential) |
0.267 |
0.22819 |
0.22505 |
0.2241 |
0.22784 |
0.22051 |
0.21642 |
0.19783 |
0.22116 |
0.21835 |
0.22243 |
|
EA (electron affinity) |
0.20124 |
0.09762 |
0.08989 |
0.09888 |
0.10612 |
0.09466 |
0.09415 |
0.08336 |
0.09487 |
0.09286 |
0.09597 |
|
Electrophilicity index (ω) |
−0.83352 |
−0.20325 |
−0.18346 |
−0.20827 |
−0.22907 |
−0.19732 |
−0.19721 |
−0.17268 |
−0.19771 |
−0.19295 |
−0.20042 |
|
Maximum charge transfer (▵Nmax) |
−7.12044 |
−2.49529 |
−2.33013 |
−2.5793 |
−2.74367 |
−2.50433 |
−2.54003 |
−2.45645 |
−2.50242 |
−2.47996 |
−2.51779 |
Figure 1Optimized structures of the hypothetical compounds A, B, and C Series.
Figure 2HOMO and LUMO representation of Compounds series A, B and C.
Molecular docking scores of A, B, C, D, and E series compounds against α‐Glucosidase, 1EVE, BChE, and SARS‐Cov2.
|
Docking score (kcal/mol) |
Docking score (kcal/mol) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
|
PDB |
AChE |
α‐Glucosidase |
BChE |
Covid |
PDB |
AChE |
α‐Glucosidase |
BChE |
Covid |
|
Comp |
1EVE |
2Q85 |
4BDS |
SARS‐Cov2 |
Comp |
1EVE |
2Q85 |
4BDS |
SARS‐Cov2 |
|
A |
−9.8616 |
−10.4651 |
−3.8288 |
−6.1 |
B |
−9.4089 |
−9.6489 |
−3.6080 |
−6.6 |
|
A1 |
−11.0342 |
−10.9790 |
−4.1174 |
−6.3 |
B1 |
−10.2806 |
−9.3785 |
−4.6419 |
−6.6 |
|
A2 |
−9.4788 |
−10.5791 |
−5.0916 |
−6.5 |
B2 |
−9.6130 |
−10.7238 |
−4.7268 |
−6.4 |
|
A3 |
−10.2108 |
−11.9404 |
−7.4276 |
−8.1 |
B3 |
−10.1952 |
−10.4317 |
−7.6919 |
−8 |
|
A4 |
−9.4405 |
−11.4668 |
−8.1407 |
−8.4 |
B4 |
−11.8063 |
−11.0378 |
−11.8123 |
−6.1 |
|
A5 |
−11.1245 |
−13.3680 |
−7.3486 |
−8.1 |
B5 |
−12.9027 |
−14.5905 |
−7.7565 |
−8 |
|
A6 |
−12.6728 |
−13.2526 |
−7.7363 |
−8.5 |
B6 |
−11.7120 |
−13.7558 |
−7.3938 |
−6 |
|
A7 |
−10.3377 |
−12.8612 |
−8.4166 |
−8.7 |
B7 |
−10.4840 |
−11.4710 |
−7.8359 |
−5.3 |
|
A8 |
−10.8511 |
−12.3068 |
−7.2407 |
−7.9 |
B8 |
−10.3633 |
−10.9823 |
−6.7436 |
−8 |
|
A9 |
−9.9035 |
−10.9808 |
−8.1118 |
−8.3 |
B9 |
−10.2838 |
−11.6716 |
−6.9841 |
−8.3 |
|
A10 |
−10.6607 |
−12.8143 |
−7.5933 |
−8.5 |
B10 |
−10.2296 |
−11.6176 |
−7.8015 |
−8.5 |
|
C |
−9.5338 |
−9.4914 |
−4.7454 |
−6.7 |
D |
−7.9471 |
−8.6886 |
−4.4428 |
−6.8 |
|
C1 |
−10.7309 |
−9.1053 |
−5.6633 |
−7.2 |
D1 |
−8.8604 |
−9.1117 |
−4.6711 |
−6.8 |
|
C2 |
−10.7609 |
−11.0101 |
−6.0197 |
−7.5 |
D2 |
−8.2461 |
−9.4299 |
−4.6681 |
−8 |
|
C3 |
−11.5058 |
−10.8187 |
−6.3557 |
−8.3 |
D3 |
−9.8060 |
−10.2411 |
−6.8175 |
−8.3 |
|
C4 |
−10.5809 |
−11.3471 |
−7.7377 |
−6.4 |
D4 |
−9.6241 |
−10.3379 |
−7.4956 |
−7.8 |
|
C5 |
−11.2874 |
−11.2233 |
−7.4393 |
−7.8 |
D5 |
−11.5847 |
−14.1575 |
−6.8445 |
−8.4 |
|
C6 |
−12.5122 |
−14.8735 |
−7.6221 |
−5.2 |
D6 |
−10.1902 |
−14.2753 |
−8.5584 |
−8.6 |
|
C7 |
−10.7113 |
−12.3032 |
−8.6971 |
−4.5 |
D7 |
−9.5292 |
−11.4683 |
−7.7214 |
−8.6 |
|
C8 |
−11.1467 |
−12.0873 |
−7.5735 |
−7 |
D8 |
−12.4249 |
−11.9791 |
−6.6595 |
−6.4 |
|
C9 |
−10.6931 |
−12.3681 |
−7.4572 |
−7.1 |
D9 |
−9.7838 |
−11.2171 |
−7.7944 |
−8.3 |
|
C10 |
−10.6083 |
−12.5190 |
−7.6422 |
−6.4 |
D10 |
−10.4985 |
−10.1050 |
−7.3026 |
−8.5 |
|
E |
−7.9093 |
−7.7439 |
−3.0744 |
−5.3 |
E6 |
−11.6638 |
−12.1622 |
−6.0738 |
−6.9 |
|
E1 |
−8.4625 |
−8.0485 |
−3.3999 |
−5.4 |
E7 |
−9.6547 |
−10.5481 |
−7.6567 |
−6.9 |
|
E2 |
−8.5450 |
−9.5494 |
−3.6798 |
−5.6 |
E8 |
−11.8103 |
−10.2132 |
−4.6790 |
−6.9 |
|
E3 |
−9.0480 |
−9.9367 |
−5.7605 |
−5.5 |
E9 |
−10.6242 |
−10.6179 |
−5.2573 |
−6.9 |
|
E4 |
−10.0965 |
−9.8762 |
−4.8084 |
−6.7 |
E10 |
−9.9540 |
−9.7010 |
−6.2178 |
−6.8 |
|
E5 |
−11.3650 |
−10.3226 |
−5.4315 |
−6.8 |
|
|
|
|
|
Figure 3The best docking complex of Spike Glycoprotein & Compound A7 possessing
Figure 4Different docking poses of the synthesized and proposed compounds on AChE.
Figure 5Different docking poses of the synthesized and proposed compounds on BChE.
Figure 6Different docking pose of the synthesized and proposed compounds on α‐glucosidase.
Figure 7Normal Mode Analysis A‐10 with Spike Protein Coronavirus (PDB ID: 6vxx). (A) Simulated 3D model (B) Deformability (C) B factor (D) Eigen values (E) Variance (F) Co‐ variance map (G) Elastic network
In‐Silico ADMET study of A serie compounds.
|
Properties |
Compounds | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
A |
A1 |
A2 |
A3 |
A4 |
A5 |
A6 |
A7 |
A8 |
A9 |
A10 |
|
Physiochemical | |||||||||||
|
Molecular weight |
225.29 |
230 |
251.32 |
313.39 |
347.84 |
329.39 |
3.59.42 |
356.46 |
329.39 |
343.42 |
327.42 |
|
No of heavy atoms |
14 |
15 |
16 |
21 |
22 |
22 |
24 |
24 |
22 |
23 |
22 |
|
Fraction Csp3 |
0.11 |
0.00 |
0.09 |
0.00 |
0.00 |
0.00 |
0.06 |
0.11 |
0.00 |
0.06 |
0.06 |
|
Num. H‐bond acceptors |
2 |
2 |
1 |
2 |
2 |
3 |
4 |
2 |
3 |
3 |
2 |
|
TPSA (Å2) |
97.93 |
97.93 |
97.93 |
97.93 |
97.93 |
118.16 |
127.39 |
101.17 |
118.16 |
107.16 |
97.93 |
|
Consensus Log |
1.67 |
2.07 |
2.34 |
3.32 |
3.86 |
2.89 |
2.93 |
3.30 |
2.89 |
3.29 |
3.64 |
|
Log S (ESOL) |
−2.79 |
−3.24 |
−3.45 |
−4.71 |
−5.30 |
−4.57 |
−4.63 |
−4.93 |
−4.57 |
−4.77 |
−5.01 |
In‐Silico ADMET study of B serie compounds.
|
Properties |
Compounds | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
B |
B1 |
B2 |
B3 |
B4 |
B5 |
B6 |
B7 |
B8 |
B9 |
B10 |
|
Physiochemical | |||||||||||
|
Molecular weight |
239.31 |
251.32 |
265.35 |
327.42 |
3.61.87 |
343.42 |
3.71.43 |
370.49 |
343.42 |
357.45 |
341.45 |
|
No of heavy atoms |
15 |
16 |
17 |
22 |
23 |
23 |
25 |
25 |
23 |
24 |
23 |
|
Fraction Csp3 |
0.20 |
0.09 |
0.17 |
0.06 |
0.06 |
0.06 |
0.06 |
0.16 |
0.06 |
0.11 |
0.11 |
|
Num. H‐bond acceptors |
2 |
2 |
2 |
2 |
2 |
3 |
4 |
2 |
3 |
3 |
2 |
|
TPSA (Å2) |
86.93 |
86.93 |
86.93 |
86.93 |
86.93 |
107.16 |
124.23 |
90.17 |
107.16 |
96.16 |
86.93 |
|
Consensus Log |
2.08 |
2.48 |
2.74 |
3.72 |
4.25 |
3.30 |
3.07 |
3.73 |
3.31 |
3.71 |
4.06 |
|
Log S (ESOL) |
−2.99 |
−3.44 |
−3.66 |
−4.92 |
−6.70 |
−4.77 |
−4.51 |
−5.15 |
−4.77 |
−4.98 |
−5.21 |
In‐Silico ADMET study of C serie compounds.
|
Properties |
Compounds | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
C |
C1 |
C2 |
C3 |
C4 |
C5 |
C6 |
C7 |
C8 |
C9 |
C10 |
|
Physiochemical | |||||||||||
|
Molecular weight |
259.35 |
271.36 |
285.38 |
347.45 |
381.90 |
363.45 |
393.48 |
390.52 |
363.45 |
377.48 |
361.48 |
|
No of heavy atoms |
17 |
18 |
19 |
24 |
25 |
25 |
27 |
27 |
25 |
26 |
25 |
|
Fraction Csp3 |
0.08 |
0.00 |
0.07 |
0.00 |
0.00 |
0.00 |
0.05 |
0.09 |
0.00 |
0.05 |
0.05 |
|
Num. H‐bond acceptors |
1 |
1 |
1 |
1 |
1 |
2 |
1 |
1 |
2 |
2 |
1 |
|
TPSA (Å2) |
77.70 |
77.70 |
77.70 |
77.70 |
77.70 |
97.93 |
107.16 |
80.94 |
97.93 |
86.93 |
77.70 |
|
Consensus Log |
3.02 |
3.41 |
3.67 |
4.61 |
5.16 |
4.17 |
4.23 |
4.59 |
4.17 |
4.60 |
4.96 |
|
Log S (ESOL) |
−4.12 |
−4.57 |
−4.78 |
−6.00 |
−6.59 |
−5.86 |
−5.92 |
−6.23 |
−5.86 |
−6.07 |
−6.30 |
In‐Silico ADMET study of D serie compounds.
|
Properties |
Compounds | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
D |
D1 |
D2 |
D3 |
D4 |
D5 |
D6 |
D7 |
D8 |
D9 |
D10 |
|
Physiochemical | |||||||||||
|
Molecular weight |
223.31 |
235.33 |
249.35 |
311.42 |
345.87 |
327.42 |
357.45 |
354.49 |
327.42 |
341.45 |
249.35 |
|
No of heavy atoms |
14 |
15 |
16 |
21 |
22 |
22 |
24 |
24 |
22 |
23 |
16 |
|
Fraction Csp3 |
0.20 |
0.09 |
0.17 |
0.06 |
0.06 |
0.06 |
0.11 |
0.16 |
0.06 |
0.11 |
0.17 |
|
Num. H‐bond acceptors |
1 |
1 |
1 |
1 |
1 |
2 |
3 |
1 |
2 |
2 |
1 |
|
TPSA (Å2) |
77.70 |
77.70 |
77.70 |
77.70 |
77.70 |
97.93 |
107.16 |
80.94 |
97.93 |
86.93 |
77.70 |
|
Consensus Log |
2.44 |
2.83 |
3.10 |
4.07 |
4.59 |
3.69 |
3.69 |
4.07 |
3.64 |
4.05 |
3.10 |
|
Log S (ESOL) |
−3.23 |
−3.68 |
−3.89 |
−5.15 |
−5.74 |
−5.01 |
−5.08 |
−5.37 |
−5.01 |
−5.21 |
−3.89 |
In‐Silico ADMET study of E serie compounds.
|
Properties |
Compounds | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
E |
E1 |
E2 |
E3 |
E4 |
E5 |
E6 |
E7 |
E8 |
E9 |
E10 |
|
Physiochemical | |||||||||||
|
Molecular weight |
188.27 |
200.28 |
214.31 |
276.38 |
310.82 |
292.38 |
322.40 |
319.44 |
292.38 |
306.40 |
290.40 |
|
No of heavy atoms |
11 |
12 |
13 |
18 |
19 |
19 |
21 |
21 |
19 |
20 |
19 |
|
Fraction Csp3 |
0.50 |
0.29 |
0.38 |
0.15 |
0.15 |
0.15 |
0.21 |
0.27 |
0.15 |
0.21 |
0.21 |
|
Num. H‐bond acceptors |
2 |
2 |
2 |
2 |
2 |
3 |
4 |
2 |
3 |
3 |
2 |
|
TPSA (Å2) |
90.06 |
90.06 |
90.06 |
90.06 |
90.06 |
110.29 |
119.52 |
93.30 |
110.29 |
99.29 |
90.06 |
|
Consensus Log |
1.17 |
1.58 |
1.87 |
2.89 |
3.44 |
2.48 |
2.53 |
2.91 |
2.48 |
2.89 |
3.23 |
|
Log S (ESOL) |
|
−2.53 |
−2.77 |
−4.13 |
−4.72 |
−3.98 |
−4.06 |
−4.37 |
−3.98 |
−4.20 |
−4.43 |